Aura Biosciences (AURA) Gains from Sales and Divestitures (2022 - 2026)
Aura Biosciences (AURA) reported Gains from Sales and Divestitures of $500744.0 for Q1 2026, up 136.46% on a YoY basis from $211770.0 in Q1 2025, and down 5.95% quarter-over-quarter from $532401.0 in Q4 2025.
Aura Biosciences (AURA) Gains from Sales and Divestitures (2022 - 2026) Analysis & Trends
Aura Biosciences has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $500744.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 136.46% year-over-year to $500744.0; the trailing twelve-month figure through Mar 2026 stood at $500744.0 (up 136.46% YoY), and the FY2025 full-year result was $532401.0, up 71.61% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $500744.0, down from $532401.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $532401.0 in Q4 2025, with the low at $43162.0 in Q4 2023.
- Historically, Gains from Sales and Divestitures has averaged $253267.9 across 5 years, with a median of $211770.0 in 2025.
- Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures declined 16.1% — and 2024, when it surged 618.79%.
- Aura Biosciences' Gains from Sales and Divestitures stood at $51444.0 in 2022, then retreated by 16.1% to $43162.0 in 2023, then surged by 618.79% to $310245.0 in 2024, then soared by 71.61% to $532401.0 in 2025, then retreated by 5.95% to $500744.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $500744.0 (Q1 2026), $532401.0 (Q4 2025), and $379970.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Aura Biosciences | 412.10 Mn | 327.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,744.00 |
| Mar 31, 2026 | 500,744.00 |
| Dec 31, 2025 | 532,401.00 |
| Dec 31, 2025 | 532,401.00 |
| Sep 30, 2025 | 379,970.00 |
| Sep 30, 2025 | 379,970.00 |
| Jun 30, 2025 | 320,519.00 |
| Jun 30, 2025 | 320,519.00 |
| Mar 31, 2025 | 211,770.00 |
| Mar 31, 2025 | 211,770.00 |
| Dec 31, 2024 | 310,245.00 |
| Dec 31, 2024 | 310,245.00 |
| Sep 30, 2024 | 200,738.00 |
| Sep 30, 2024 | 200,738.00 |
| Jun 30, 2024 | 144,831.00 |
| Jun 30, 2024 | 144,831.00 |
| Mar 31, 2024 | 90,123.00 |
| Mar 31, 2024 | 90,123.00 |
| Dec 31, 2023 | 43,162.00 |
| Dec 31, 2023 | 43,162.00 |